Intravesical Gemcitabine Versus Mitomycin C for Non-Muscle Invasive Bladder Cancer: A Robust Meta-Analysis Revealing Superior Recurrence Control and Improved Tolerability.

Journal of Pioneering Medical Science 2026 Open access

Read full text
Authors: Mohamed S. Imam, Manar Mesfer Eid Alsaadi, Hadeel Saad Althagafi, Norah Khalid Abdullah Humaish, Atheer S Alotaibi, Amjad Homoud Masoud Alotaibi, Lujain Mneef Salm Almalki, Daniyah Mansour Abdulaziz Alazwari, Mahdi Mohammed Ahmed Aljamaan, Latifa Fahad Abdalwahap Almohsin, Haliah Khaliad Mohamed Alfayez, Lama A. Alamri
+3 more Myasah Musleh Saif Altamimi, Bashayer A. Alkhathlan, Khalid Sultan Allahyani
DOI: 10.47310/jpms2026150101
Cited by: 0
References: 33

Abstract

Background: Non-Muscle Invasive Bladder Cancer (NMIBC) constitutes the majority of bladder cancer patients but has elevated recurrence rates after intravesical treatment. Although mitomycin C (MMC) is extensively used, intravesical gemcitabine (GCB) has shown potential as a superior option with enhanced tolerability. Objective: This meta-analysis compares the effectiveness and safety of intravesical GCB versus MMC for NMIBC management. Methods: Following PRISMA guidelines, seven studies with 491 patients were analyzed. Outcomes included tumor recurrence, chemical cystitis and hematuria. Fixed-effects or random-effects models were used to compute pooled Odds Ratios (ORs) with 95% Confidence Intervals (CIs). Results: GCB significantly reduced recurrence rates compared to MMC (OR: 2.97; 95% CI: 1.90-4.65; p

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Urinary Bladder and Prostate Research Urinary and Genital Oncology Studies

Publication details

Journal / source
Journal of Pioneering Medical Science
Volume
15
Issue
01
Pages
1–11
Publication date
5 February 2026
Language
EN